RLMD - Relmada Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
40.01
-1.99 (-4.74%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close42.00
Open41.44
Bid39.00 x 800
Ask0.00 x 1200
Day's Range39.99 - 43.00
52 Week Range4.40 - 48.00
Volume91,354
Avg. Volume137,217
Market Cap411.115M
Beta (3Y Monthly)-0.09
PE Ratio (TTM)N/A
EPS (TTM)-2.21
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • Benzinga

    The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...

  • Benzinga

    The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...

  • Relmada Therapeutics Announces Pricing of Public Offering of Common Stock
    PR Newswire

    Relmada Therapeutics Announces Pricing of Public Offering of Common Stock

    Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the pricing of an offering of 3,333,334 shares of its common stock at a public offering price of $30.00 per share in an underwritten offering. The gross proceeds to Relmada from the offering, before deducting underwriting discounts and commissions and other estimated expenses payable by Relmada, are expected to be $100,000,020. In addition, Relmada has granted the underwriters a 30-day option to purchase up to an additional 500,000 shares of Relmada's common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 6, 2019, subject to customary closing conditions.

  • Relmada Therapeutics Announces Proposed Public Offering of Common Stock
    PR Newswire

    Relmada Therapeutics Announces Proposed Public Offering of Common Stock

    Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. Relmada also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering.

  • PR Newswire

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Nov. 19, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • What Kind Of Shareholder Appears On The Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Shareholder Register?

    The big shareholder groups in Relmada Therapeutics, Inc. (NASDAQ:RLMD) have power over the company. Institutions often...

  • Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
    PR Newswire

    Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18

    NEW YORK , Oct. 17, 2019 /PRNewswire/ -- Relmada Therapeutics Inc. (NASDAQ: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, announced today ...

  • MarketWatch

    Relmada Therapeutics stock rockets 137% on positive trial of depression treatment

    Relmada Therapeutics Inc. shares soared 137% Tuesday, after the clinical-stage biotech reported positive results from a midstage trial of a treatment for depression. New York-based Relmada said the Phase 2 trial of REL-1017 showed statistically significant improvement for patients suffering from treatment resistant depression versus placebo. "We are very pleased to announce these highly compelling results," said Dr. Ottavio Vitolo, Relmada head of R&D and CMO. "This is the first clinical evidence that REL-1017 exerts a rapid and robust antidepressant effect, which continues even after treatment discontinuation." REL-1017, or dextromethadone, is a rapidly acting oral agent that works as an NMDA receptor antagonist and on the same binding site as ketamine, but without the side effects that are associated with ketamine. The U.S. Food and Drug Administration has granted the drug fast track designation. Shares have gained 476% in 2019, while the S&P 500 has gained 19%.

  • Benzinga

    Relmada Shares Hit 4-Year High As Depression Drug Aces Midstage Trial

    New York-based Relmada released top-line data from a Phase 2 study that evaluated its REL-1017-202, chemically dextromethadone, in 25mg once a day and 50mg daily doses as an adjunctive treatment in patients with treatment-resistant depression, or TRD. The 62 subjects enrolled in the study had an average age of 49.2 years, an average Hamilton Depression Rating Scale score of 25.3 and an average Montgomery-Asberg Depression Rating Scale score of 34, reflecting severe depression.

  • Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
    PR Newswire

    Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

    Findings show that REL-1017 has rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures NEW YORK , Oct. 15, 2019 /PRNewswire/ ...

  • Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
    PR Newswire

    Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15

    NEW YORK , Oct. 14, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced ...

  • Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market
    PR Newswire

    Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market

    Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf.

  • Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market
    PR Newswire

    Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market

    NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB:RLMDD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the Company's common stock has been approved for listing on The Nasdaq Capital Market. "The listing of our stock on The Nasdaq Capital Market represents a substantial milestone for our company," said Sergio Traversa, CEO of Relmada Therapeutics. Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases.

  • Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
    PR Newswire

    Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

    NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that its Board of Directors has approved a 1-for-4 reverse stock split of the company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective with the Financial Industry Regulatory Authority (FINRA) and in the marketplace on September 30, 2019, whereupon the shares of common stock will begin trading on a split-adjusted basis. "This reverse stock split is an important step in Relmada's corporate development as the maintenance of a minimum closing bid price of $4.00 would fulfill the share price requirement for an uplisting to NASDAQ," stated Sergio Traversa, CEO of Relmada Therapeutics.

  • Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
    PR Newswire

    Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression

    NEW YORK, July 29, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the last subject has completed dosing with REL-1017 (dextromethadone) in the company's  double-blind, placebo-controlled Phase 2 clinical study evaluating the safety and efficacy of REL-1017 as an adjunctive treatment in patients affected by treatment-resistant depression. "We are very excited to have achieved this important milestone in the clinical development of REL-1017 for major depressive disorder," said Dr. Ottavio Vitolo, Relmada Head of R&D and CMO. Thus far, the blinded data confirms the favorable safety and tolerability profile of REL-1017 previously observed in the Phase 1 studies.

  • Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles
    PR Newswire

    Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles

    NEW YORK, June 3, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it will present an overview of the company's business operations and progress in clinical research and product development at the LD Micro Invitational Conference on Wednesday, June 5, 2019 at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. The presentation by Sergio Traversa, CEO of Relmada Therapeutics, is scheduled to begin at 11:40 a.m. PT (2:40 p.m. Eastern Time). A live webcast of the presentation will be available through the Company's website at www.relmada.com.

  • Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting
    PR Newswire

    Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting

    NEW YORK, May 31, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that a review of the company progress in the development of REL1017 (d-methadone, dextromethadone) for the treatment of depression and other CNS disorders was presented this week during the 2019 American Society of Clinical Psychopharmacology meeting in Scottsdale, AZ. The poster presentation entitled, "Development of the N-Methyl-D-Aspartate Receptor (NMDAR) Antagonist d-Methadone (REL 1017) for the Treatment of Depression and Other CNS Disorders", reported previously announced results from multiple pre-clinical studies comparing the effects of d-methadone and ketamine in different behavioral animal models used to assess antidepressant activity.  Results showed that d-methadone produced improvements similar to ketamine across a range of key tests, including Forced Swim Test, Female Urine Sniffing Test, Novelty Suppressed Feeding Test, and a Chronic Unpredictable Stress protocol.

  • Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
    PR Newswire

    Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results

    NEW YORK, April 16, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that results of its N-methyl-D-aspartate receptor (NMDAR) antagonist REL1017 (dextromethadone) single ascending dose and multiple ascending dose studies were accepted for publication in the peer reviewed  Journal of Clinical Psychopharmacology.  REL1017 is Relmada's lead product candidate currently in a Phase 2 study in individuals with major depressive disorder (MDD) who have not responded to traditional antidepressants.

  • Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
    PR Newswire

    Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations

    NEW YORK, April 3, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Gina DiGuglielmo has joined the company as vice president and head of clinical operations. Ms. DiGuglielmo previously served as clinical operations advisor of Relmada since June 2017.  In her new role, Ms. DiGuglielmo will lead and oversee the clinical operations for Relmada's lead product candidate dextromethadone (REL-1017), a novel N-methyl-D-aspartate (NMDA) receptor antagonist in development as a rapid acting treatment of depression and potentially other CNS indications and will contribute to the advancement of the company's portfolio in the clinical phases.

  • Relmada Therapeutics to Present at Biotech Showcase 2019
    PR Newswire

    Relmada Therapeutics to Present at Biotech Showcase 2019

    NEW YORK, Jan. 2, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that it will present at Biotech Showcase 2019 to be held January 7-9, 2019, at the Hilton San Francisco Union Square. A live webcast of the presentation will be available through the Company's website at www.relmada.com.  Please register at least 10 minutes prior to the start of the presentation to ensure timely access.

  • Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017
    PR Newswire

    Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017

    NEW YORK, Dec. 12, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that clinical data demonstrating increased plasma levels of brain derived neurotrophic factor (BDNF) in healthy subjects treated with REL-1017 (dextromethadone) were presented at the annual American College of Neuropsychopharmacology meeting. REL-1017 is an orally available N-methyl-D-aspartate (NMDA) receptor antagonist with potential rapid onset efficacy in individuals with depression and treatment resistant depression.